Literature DB >> 18343741

Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?

A C Galles1, R N Jones, H S Sader.   

Abstract

The susceptibility profile of 763 Stenotrophomonas maltophilia isolates was evaluated against 16 antimicrobials by the CLSI reference broth microdilution method. Minocycline (MIC(90), 1 microg/ml; 100.0% susceptible) was the most active compound, followed by doxycycline (MIC(90), 4 microg/ml; 99.6% susceptible), trimethoprim/sulfamethoxazole (MIC(90), 1 microg/ml; 97.8% susceptible), and tigecycline (MIC(90), 2 microg/ml). An excellent correlation between levofloxacin (MIC(90), 4 microg/ml; 86.5% susceptible by published breakpoint criteria) and moxifloxacin (MIC(90), 2 micro g/ml) MIC results was observed indicating that moxifloxacin could be further evaluated as a therapeutic option for S. maltophilia infections.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18343741     DOI: 10.1179/joc.2008.20.1.38

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  7 in total

1.  Trimethoprim/Sulfamethoxazole and Moxifloxacin Therapy for a Pediatric Stenotrophomonas Maltophilia Ventriculoperitoneal Shunt Infection.

Authors:  Eric R Gregory; Sam B Osborne; Brian M Gardner; Robert A Broughton
Journal:  J Pediatr Pharmacol Ther       Date:  2019 Jan-Feb

Review 2.  Stenotrophomonas maltophilia: Significant contemporary hospital pathogen - review.

Authors:  O Nyc; J Matejková
Journal:  Folia Microbiol (Praha)       Date:  2010-06-06       Impact factor: 2.099

3.  Predicting antibiotic resistance to community-acquired pneumonia antibiotics in culture-positive patients with healthcare-associated pneumonia.

Authors:  Karl J Madaras-Kelly; Richard E Remington; Vincent S Fan; Kevin L Sloan
Journal:  J Hosp Med       Date:  2011-10-28       Impact factor: 2.960

4.  Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from a Korean tertiary care hospital.

Authors:  Hae-Sun Chung; Seong Geun Hong; Yangsoon Lee; Myungsook Kim; Dongeun Yong; Seok Hoon Jeong; Kyungwon Lee; Yunsop Chong
Journal:  Yonsei Med J       Date:  2012-03       Impact factor: 2.759

5.  Current Situation of Antimicrobial Resistance and Genetic Differences in Stenotrophomonas maltophilia Complex Isolates by Multilocus Variable Number of Tandem Repeat Analysis.

Authors:  Ji Young Rhee; Jae Hoon Song; Kwan Soo Ko
Journal:  Infect Chemother       Date:  2016-12

6.  Clinical and Epidemiological Characteristics of Stenotrophomonas maltophilia Associated Lower Respiratory Tract Infections in Qatar: A Retrospective Study.

Authors:  Arun P Nair; Sreethish Sasi; Muna Al Maslamani; Abdullatif Al-Khal; Kadavil Chacko; Anand Deshmukh; Mohammed Abukhattab
Journal:  Cureus       Date:  2022-03-17

7.  Antimicrobial susceptibility of stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates.

Authors:  Hae-Sun Chung; Seong Geun Hong; Young Ree Kim; Kyeong Seob Shin; Dong Hee Whang; Jee Young Ahn; Yeon-Joon Park; Young Uh; Chulhun L Chang; Jong Hee Shin; Hye Soo Lee; Kyungwon Lee; Yunsop Chong
Journal:  J Korean Med Sci       Date:  2013-01-08       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.